Literature DB >> 19921530

The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus.

Jeong-Yeol Park1, Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam.   

Abstract

AIMS: To determine the incidence of lymph node (LN) metastasis in patients with apparently early carcinosarcoma of the uterus, to analyze the clinicopathologic factors associated with LN metastasis, and to evaluate the role of pelvic and/or para-aortic lymphadenectomy in treatment of such conditions.
METHODS: We retrospectively analyzed 41 patients with carcinosarcoma intraoperatively confined to the uterus who underwent complete staging procedures including pelvic and/or para-aortic lymphadenectomy.
RESULTS: After surgery, two patients (4.9%) were upstaged to stage IIIA because of positive peritoneal washing cytology, and 13 (31.7%) were upstaged to stage IIIC as a result of LN metastasis. Five patients had pelvic, three had paraaortic, and five had both pelvic and para-aortic LN metastases. The mean number of metastatic LNs was 3.7 (range 1-15). On multivariate analysis, myometrial invasion >1/2 [odds ratio (OR) 8.50; 95% confidence interval (CI) 1.57-45.92; P = 0.013] and lymphovascular space invasion (LVSI) (OR 8.50; 95% CI 1.57-45.92; P = 0.013) were significantly predictive of LN metastasis. After a median follow-up interval of 32 months (range 3-179 months), the 2-year disease-free survival (DFS) and overall survival (OS) rates were 73% and 84%, respectively, and the 5-year DFS and OS rates were 73% and 69%, respectively. Patients with LVSI or LN metastasis had significantly poorer DFS and OS.
CONCLUSIONS: Pelvic and para-aortic lymphadenectomy should be performed in patients with apparently early carcinosarcoma of the uterus, especially in those with myometrial invasion >1/2 or LVSI.

Entities:  

Mesh:

Year:  2010        PMID: 19921530     DOI: 10.1245/s10434-009-0833-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.

Authors:  Yavuz Emre Şükür; Salih Taşkın; Bulut Varlı; Can Ateş; Mete Güngör; Fırat Ortaç
Journal:  Int J Clin Oncol       Date:  2017-08-23       Impact factor: 3.402

Review 2.  Review of Recommended Treatment of Uterine Carcinosarcoma.

Authors:  Joseph Menczer
Journal:  Curr Treat Options Oncol       Date:  2015-11

3.  Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.

Authors:  Kenichi Harano; Akihiro Hirakawa; Mayu Yunokawa; Toshiaki Nakamura; Toyomi Satoh; Tadaaki Nishikawa; Daisuke Aoki; Kimihiko Ito; Kiyoshi Ito; Toru Nakanishi; Nobuyuki Susumu; Kazuhiro Takehara; Yoh Watanabe; Hidemichi Watari; Toshiaki Saito
Journal:  Int J Clin Oncol       Date:  2015-06-18       Impact factor: 3.402

4.  A Study of Prognostic Factors of Chinese Patients with Gynecologic Tract Carcinosarcomas Prognosis of Gynecologic Carcinosarcomas.

Authors:  Dan Ye; Hao-Ran Shen; Liangqing Yao
Journal:  Cancer Manag Res       Date:  2020-10-29       Impact factor: 3.989

5.  A cohort study evaluating paraaortic lymphadenectomy in endometrial cancer.

Authors:  Haiyan Zhang; Zhi Zuo; Ye Wang; Li Wang; Zhiling Zhu
Journal:  Oncol Lett       Date:  2012-09-17       Impact factor: 2.967

6.  Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

Authors:  Ai Otsuki; Takeo Otsuki; Hideki Tokunaga; Hitoshi Niikura; Satoru Nagase; Takashi Sugiyama; Masafumi Toyoshima; Hiroki Utsunomiya; Yoshihito Yokoyama; Hideki Mizunuma; Naoki Sato; Yukihiro Terada; Tadahiro Shoji; Toru Sugiyama; Kenji Nakahara; Tsuyoshi Ohta; Hidekazu Yamada; Toru Tase; Hiroshi Nishiyama; Keiya Fujimori; Tadao Takano; Fumiaki Takahashi; Yoh Watanabe; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2014-07-18       Impact factor: 3.402

7.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Authors:  D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

8.  Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas.

Authors:  Kemal Gungorduk; Aykut Ozdemir; Ibrahim E Ertas; Mehmet Gokcu; Elcin Telli; Tufan Oge; Ahmet Sahbaz; Sevil Sayhan; Muzaffer Sanci; Mehmet Harma; Sinan Ozalp
Journal:  Cancer Res Treat       Date:  2014-09-04       Impact factor: 4.679

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.